P

obiotics are living microorganisms that, on ingestion in sufficient numbers, exert health benefits beyond the metabolic effect of nutritional components. It has been suggested that probiotic bacteria are effective and promising agents for the treatment of inflammatory gastrointestinal barrier disorders, including infectious colitis, antibiotic associated diarrhoea, and inflammatory bowel diseases (IBD). In recent years a series of placebo controlled randomised clinical trials have been conducted demonstrating the clinical efficacy of probiotics. However, understanding of the mechanism of action of probiotic bacteria is still incomplete. In vitro and animal studies have shown that probiotics influence epithelial barrier function and gut permeability, restore the commensal bacterial microbiota, and reduce the production of inflammatory cytokines. Induction of anti-inflammatory cytokine expression, probably through modification of bacterial signalling in epithelial cells, has also been suggested. This hypothesis is supported by the efficacy of local delivery of anti-inflammatory cytokines in animal models.

Functional experiments using animal models suggest that probiotics may have profound effects on the composition of the faecal flora well beyond insertion of new bacterial strains. However, the effects of probiotic bacteria on the resident mucosa related intestinal microbiota that is directly interacting with the host mucosal barrier organ is poorly understood. Culture based methods have identified a maximum of 10–30% of the bacterial spectrum (and probably less than 10% of fungal species) of the complex bacterial community in the human gut. Molecular techniques may overcome these limitations. The 16S/18S rRNA marker gene system has been employed previously to analyse the bacterial communities of the intestine and to investigate the dominant species using oligonucleotide hybridisation, real time polymerase chain reaction (PCR), and fluorescent in situ hybridisation (FISH). Community fingerprinting techniques have been shown to be a powerful tool for determining microbial diversity in complex samples.

Ulcerative colitis (UC) is a subform of IBD, a group of chronic recurrent gastrointestinal inflammatory barrier diseases. Restorative proctocolectomy with ileal pouch anal anastomosis is a well established procedure in the surgical treatment of UC and familial adenomatous polyposis. Approximately 15–46% of patients with UC develop pouchitis, a major complication after ileal pouch anal anastomosis, within five years of operation. A chronic relapsing form of pouchitis can be distinguished from a chronically active form. The aetiology and pathophysiology of pouchitis are still unknown. Interaction between the mucosal immune system and the gut flora appears to play a crucial role in the initiation of pouchitis. Alterations of the bacterial microbiota may be an important factor triggering the disease process and may explain the efficacy of antibiotic treatment in pouchitis. However, remission periods are often short and the condition is complicated by frequent relapses.
studies have shown that probiotic treatment with VSL#3, a mixture of eight different probiotic bacterial strains, is effective in maintaining remission in pouchitis.\textsuperscript{52-54}

A subset of patients (n = 15), who had participated in a double blind, randomised, placebo controlled clinical trial, were investigated.\textsuperscript{52} Patients with pouchitis in remission that had been induced by antibiotic therapy were recruited to receive either the VSL#3 probiotic compound or placebo for maintenance of remission. Biopsies were obtained before and two months after initiation of VSL#3 or placebo treatment. Probiotic therapy with VSL#3 increased the total number of intestinal bacterial cells as well as the richness and diversity of the bacterial microbiota, especially the anaerobic flora, whereas the fungal flora was repressed. In contrast, patients who relapsed while receiving placebo showed reduced diversity of the mucosal flora.

**MATERIAL AND METHODS**

**Patients**

Patients with recurrent or chronic active pouchitis, who were enrolled in a placebo controlled, randomised, remission maintenance trial with the probiotic preparation VSL#3\textsuperscript{52} were recruited for this substudy. The main inclusion criterion was prior successful induction of remission (defined as a pouchitis activity index of 0 or 1) by therapy with metronidazole and ciprofloxacin.\textsuperscript{52} Fifteen of 36 patients in the trial agreed to have additional biopsies for this study, taken for exploration of the mucosal microbiota. Pouchitis was defined by histological and endoscopic criteria using the pouchitis disease activity index (PDAI).\textsuperscript{52} Age ranged from 22 to 64 years (median 34) in the 15 patients; there were six females and nine males. Total PDAI (expressed as medians) was 3 (1–7) at study entry in both groups.

Patients received VSL#3 (VSL pharmacies Inc., Gaitherburg, Maryland, USA) 6 g once daily or identical placebo for 12 months. VSL#3 contains 300 billions viable lyophilised bacteria per gram, comprising four strains of lactobacilli (Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of bifidobacteria (Bifidobacterium infantis, Bifidobacterium longum, and Bifidobacterium breve), and one strain of streptococcus (Streptococcus salivarius subspecies thermophilus). Placebo sachets contained maize without bacteria but did not differ in taste or physical appearance from VSL#3.

Mucosal biopsies were obtained during pouch endoscopy and immediately snap frozen in liquid nitrogen. Patients were studied before and after two months of therapy with study medication. Of the 15 patients recruited for the substudy, 10 received VSL#3 and five placebo. All VSL#3 patients in this substudy were still in remission after two months while all placebo patients showed signs of active pouchitis. All clinical and molecular examinations were carried out, and the results collated before the trial was unblinded.

**Treatment of biopsy samples and DNA extraction**

Biopsy and stool specimens were immediately snap frozen in liquid nitrogen after colonoscopy. DNA was extracted following a protocol adapted to the characteristics of the microorganisms\textsuperscript{52}: biopsies were incubated with 200 µl TL-buffer (200 mM REPES, pH 7.5, 1 M KCl, 100 mM MgCl\textsubscript{2}, 1 mM EDTA, 0.2% Na\textsubscript{2}EDTA, and 25 µl proteinase K (PeqLab, Erlangen, Germany)) at 55°C for two hours. DNA was extracted using the FastDNA Spin Kit for soil after mechanical homogenisation (FastPrep FP 120 instrument) according to the manufacturer’s instructions (both BIO 101, Carlsbad, California, USA). For sensitive and accurate quantification, DNA concentrations were determined using PicoGreen according to the manufacturer’s guidelines (dsDNA quantification kit; Molecular Probes, Leiden, the Netherlands).

**Real time PCR**

The real time PCR assay used in this study has been described previously.\textsuperscript{57} Amplification and detection were carried out in 96 well optical plates on an ABI PRISM 7700 Sequence Detector with TaqMan Universal PCR 2× Master Mix, primer (0.4 µM), probe (0.2 µM), and 20 ng of sample DNA in a final volume of 50 µl per reaction. The universal probe UNI (5’-ACT GAC ACA CGG TCC A-3’) binds to position 321-37 and is VIC labelled. In the present study, minor groove binder fluorescent probes with non-fluorescent quencher dyes (also called “dark” quencher) were used (Applied Biosystems, Foster City, California, USA). SDS software v1.7 or later was used to support non-fluorescent quencher probes. The universal primers used in this study hybridise to conserved regions on the 16S gene. The forward primer TP1U (5’-AGA GTG TCA TGM TGG CTC AG-3’) binds to position 8-27 and the reverse primer RTUB (5’- AAG GAG GTG ATC CAN CCR CA-3’) binds to position 1522-41 (Escherichia coli reference numbering). The absolute number of cells was normalised to the total amount of DNA extracted from each biopsy. The total number of cells was interpolated from the averaged standard curve as described.\textsuperscript{52-54}

**Single strand conformational polymorphism (SSCP) analysis**

For initial PCR, the two conserved primers COM-1 (5’-CAG CAG CCG TAA TAC TAC-3’, position 519-536 on the reference E coli 16S gene) and Com2-Ph (5’-CCG TCA ATT CCT TTG AGT TTG TAC-3’, position 907-926 on the reference E coli 16S gene) were used, as published by Schwieger and Tebbe.\textsuperscript{56} PCR products were controlled for size and products by agarose gel electrophoresis. Preparation of single stranded DNA and silver staining of SSCP gels were performed according to Schwieger and Tebbe.\textsuperscript{56} Image editing and normalisation were performed using GelCompare II-software (Applied Maths, Kortrijk, Belgium). The general diversity of bacterial species was calculated according to Shannon and Weaver, as described previously.\textsuperscript{56}

**Denaturing gradient gel electrophoresis (DGGE) analysis**

For PCR amplification of 18S rRNA fragments (1.650 bp), the two fungus specific primers NS1 (5’-CA TCG CAC TAC TAC CTT AGT-3’) and FR1-GC (5’-GGG GCC CCG CGG CGG CGG GCC GGG GCC GCC GCA GCA GCA CCT AAC CGB TAI T-3’) were used, as published by Vainio and Hantula.\textsuperscript{59} DGGE analysis and silver staining were performed according to Newton and colleagues.\textsuperscript{56} Image editing, normalisation, and calculation of diversity indices were carried out as described above.

**Sequencing of bands from SSCP/DGGE community profiles**

To identify the bacteria correlated with the bands, selected products from the polyacrylamide gel after silver staining were excised with sterile scalpels. Gel slices were then mixed with elution buffer. After incubation, 5–20 µl of sample DNA were digested with 0.3 U SAP (shrimp alkaline phosphatase) and 8% agarose gel electrophoresis, 8 µl of the PCR products were digested with 0.3 U SAP (shrimp alkaline phosphatase) and 1.5 U ExoI. The sequencing reaction was performed on an ABI PRISM 3700 DNA Analyser using 1 µl of ABI PRISM BigDye (Applied Biosystems), 30 µM concentration of each sequencing primer (Eurogentec Seraing, Belgium), and 2 µl of digested PCR product. Forward and reverse sequences were added to the sequencing reaction. The PCR products were sequenced in the forward and reverse direction and the sequences were compared to the GenBank database using the BLAST algorithm (National Centre for Biotechnology Information, USA).
were aligned with Sequencher software package (Gene Codes Corp., Ann Arbor, Michigan, USA). Fragments were identified by NCBI BLAST database search.

**Group specific clone libraries**

Group specific clone libraries for the following bacterial taxa were generated: Lactobacillus, Bilfdobacterium, Bacteroides/Prevotella, and γ-Proteobacteria/Enterobacteriaceae (for primer information see table 1). More than 600 clones were sequenced from 12 independent taxa specific libraries (Lactobacillus n = 135, Bilfdobacterium n = 136, Bacteroides/Prevotella n = 124, and γ-Proteobacteria/Enterobacteriaceae n = 236) that were generated from pooled disease related (before study therapy, placebo, VSL#3) PCR products. A two step reconditioning PCR approach (35/10 cycles) was used as described elsewhere. The specific fragment of the 16S rDNA was amplified and cloned into E.coli cells using the PCR 2.1 TOPO TA Cloning Kit for sequencing (Invitrogen, Karlsruhe, Germany), as described previously.

Cloning and sequencing of inserts was performed using 3.2 pmol of M13F and M13R sequencing primers (table 1), as described previously. Alignment, assembly, and trimming of vector sequences were performed using the Sequencher software package (Gene Codes Corp.). Sequences were checked for vector contamination using the NCBI VecScreen tool. OTUs were identified by NCBI BLAST analysis using search results of at least 97% similarity. Sequences were examined for chimera using the Chimera Check tool of the Ribosomal Data Projects (RDP) of the Center for Microbial Ecology, Michigan State University, Michigan, USA.

**Fluorescent in situ hybridisation (FISH) and oligonucleotide probes**

Biopsies were fixed in 500 μl of freshly prepared 4% buffered formalin and embedded in Histoplast (Sigma, St Louis, Missouri, USA) according to routine procedures. Cross sections (2 μm) were cut and placed on coated microscope slides (Superfrost™/Plus). Sections were hybridised as described previously using the following 16S/23S rRNA targeted oligonucleotide probes: (1) an equimolar mixture of five bacteria directed probes EUB 338, EUB 785, EUB 927, EUB 1055, and EUB 1688 (58, 59), referred to as EUB mix, to detect all bacteria; (2) Bac 305 to detect the Bacteroides/Prevotella cluster; (3) Erec 482 specific for most of the Clostridia and eubacteria belonging to the Clostridium cocoides -Eubacterium rectale group; (4) bifidobacterial probe Bif 164; (5) Lab 158 for nearly all species of the genera Lactobacillus and Enterococcus in the gut; and Ec 1531 specific for a number of Enterobacteriaceae (for example, Escherichia coli, Klebsiella pneumonia). The oligonucleotides were 5' labelled with the indocarbocyanine dye Cy3 (Thermo Hybaid GmbH, Waltham, Massachusetts, USA).

---

**Table 1 Oligonucleotides used for the group specific clone libraries**

<table>
<thead>
<tr>
<th>Bacterial group</th>
<th>Primer</th>
<th>Direction</th>
<th>Position</th>
<th>Sequence (5'→3')</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactobacillus</td>
<td>Lac1</td>
<td>Forward</td>
<td>352–370*</td>
<td>ACCGATAGGAAGACCTTTCA</td>
<td>Walter</td>
</tr>
<tr>
<td></td>
<td>Lac2</td>
<td>Forward</td>
<td>679–680*</td>
<td>ATYYACCGCTACACATG</td>
<td>Walter</td>
</tr>
<tr>
<td>Bilfdobacterium</td>
<td>Bif.164</td>
<td>Forward</td>
<td>164–181*</td>
<td>GGGTGCTGAACTGGGCGATG</td>
<td>Langendijk</td>
</tr>
<tr>
<td>Bacteroides/Prevotella</td>
<td>Bif.662</td>
<td>Reverse</td>
<td>679–662*</td>
<td>TCCACCCTTACACCGGAAA</td>
<td>Langendijk</td>
</tr>
<tr>
<td></td>
<td>Bac.32</td>
<td>Forward</td>
<td>32–50*</td>
<td>AACGCTAATACAGCCTT</td>
<td>Bernhard</td>
</tr>
<tr>
<td></td>
<td>Bac.303</td>
<td>Reverse</td>
<td>303–321*</td>
<td>CAAAGTGGGGACCTTC</td>
<td>Manz</td>
</tr>
<tr>
<td>γ-Proteobacteria/Enterobacteriaceae</td>
<td>TPUS F</td>
<td>Forward</td>
<td>906–26*</td>
<td>AAACCTAAATAGGATCGG</td>
<td>Wintzingerode</td>
</tr>
<tr>
<td></td>
<td>Ent.1416</td>
<td>Reverse</td>
<td>1416–23*</td>
<td>CTTGTCGACCATCCTC</td>
<td>Sghir</td>
</tr>
<tr>
<td>Sequencing</td>
<td>M13 (21)</td>
<td>Forward</td>
<td>389–404†</td>
<td>TGTTAAAACGGACGGCAGT</td>
<td>Guntram</td>
</tr>
<tr>
<td></td>
<td>M13 (24)</td>
<td>Reverse</td>
<td>208–25†</td>
<td>AACAGCTATAGGACATG</td>
<td>Guntram</td>
</tr>
</tbody>
</table>

*Position referring to the Escherichia coli reference sequence.
†M13 priming sites on pCR 2.1 plasmid vector.

---

**Figure 1** Bacterial diversity indicated as richness (No of bands) and diversity indices, obtained from single strand conformational polymorphism profiles of pouchitis patients in remission before randomisation (after treatment with antibiotics), after placebo (no therapy), and after VSL#3. For each group, the mean (SD) number of bands are shown. Bacterial diversity of the probiotic group was significantly higher compared with the starting value (p = 0.02).

**Figure 2** Treatment with VSL#3 significantly increased the number of 16Sr DNA copies compared with pretreatment samples and placebo (p = 0.002, p = 0.013, respectively).
Lactobacillus flora in remission (after antibiotic therapy), after placebo, and after VSL#3 therapy, as assessed by analysis of clone libraries. A total of 136 clones were randomly picked and sequenced.

Expression of data

Normally distributed data are expressed as mean (SD), if not indicated otherwise. Statistical significance of the differences was examined using the Student’s t test for normally distributed data and the Mann Whitney U test or the Wilcoxon matched pairs test for non-normally distributed data. Distribution of data was evaluated by calculating Lilliefors probabilities based on the Komolgorov-Smirnov test.

RESULTS

Patients

Fifteen patients in remission induced by antibiotic therapy participated in this substudy (out of 36 participating in a double blind, randomised, placebo controlled trial of VSL#3 in pouchitis maintenance). No signs of morphological or histological inflammation were seen, as required by the inclusion criteria. The 10 patients who received VSL#3 were verified as being in remission at the time of the second biopsy (two months) while all five patients who were receiving placebo showed clinical and endoscopic signs of recurrent inflammation.

SSCP analysis and real time PCR of the bacterial microbiota

SSCP fingerprinting analysis of 16S rDNA fragments showed low bacterial richness and diversity in mucosal biopsies from patients at study entry after antibiotic induction of remission in comparison with normal colon. Probiotic therapy with VSL#3 increased bacterial richness and diversity of the pouch mucosal flora compared with both patients in remission before therapy and patients developing pouchitis while receiving placebo. The difference in bacterial diversity between patients before and after therapy with VSL#3 was statistically significant (p = 0.02) (fig 1). A universal real time PCR that amplified 16S rDNA was then used to compare the total number of bacterial cells. Treatment with VSL#3 caused a statistically significant increase in the number of 16S rDNA copies compared with pretreatment remission (n = 10, p = 0.002) and placebo treatment (n = 5, p = 0.013), as shown in fig 2. Separate statistical analysis showed no correlation between results of the SSCP analysis and real
Enterobacteriaceae
Lactobacillus mucosae

The 16S rRNA targeted oligonucleotide mixture EUB that globally detects bacteria was used in tissue sections from pouch mucosal biopsies. Subdifferentiation was carried out using a set of specific oligonucleotide probes. Almost all bacteria detected were classified as Enterobacteriaceae whereas the Lactobacillus/Enterococcus probes resulted only in occasional detection of signals in VSL#3 treated patients. The figure is a representation of six experiments per group (VSL#3 and placebo, before and after treatment). Mucosal biopsies in patients in remission prior to study drug therapy showed high numbers of intraepithelial bacteria (A). Colonisation was reduced after placebo treatment, which was accompanied by relapse of inflammation (B). Bacterial colonisation of the epithelium was maintained during VSL#3 treatment (C).

**Figure 6** γ-Proteobacteria/Enterobacteriaceae flora in remission (after antibiotic therapy), after placebo, and after VSL#3 therapy, as assessed by clone libraries. A total of 236 clones were randomly picked and sequenced because of the expected higher diversity. The graph shows the percentage of single species identified by BLAST analysis. The diversity of Enterobacteriaceae, especially Enterobacter species and Escherichia coli, was higher in the placebo and VSL#3 groups but there were only slight differences between these two groups. Remarkably, there was a high proportion of Pseudomonas species in the group before study therapy, which could be due to overgrowth induced by antibiotic selection pressure.

**Figure 7** The 16S rRNA targeted oligonucleotide mixture EUB that globally detects bacterial sequences was used in tissue sections from pouch mucosal biopsies. Subdifferentiation was carried out using a set of specific oligonucleotide probes. Almost all bacteria detected were classified as Enterobacteriaceae whereas the Lactobacillus/Enterococcus probes resulted only in occasional detection of signals in VSL#3 treated patients. The figure is a representation of six experiments per group (VSL#3 and placebo, before and after treatment). Mucosal biopsies in patients in remission prior to study drug therapy showed high numbers of intraepithelial bacteria (A). Colonisation was reduced after placebo treatment, which was accompanied by relapse of inflammation (B). Bacterial colonisation of the epithelium was maintained during VSL#3 treatment (C).
of these organisms was found. In contrast, recurrent inflammation during placebo treatment was associated with a reduction in the presence of Enterobacteriaceae (Fig 4). No signals were detected with the Bacteroides/Prevotella, Clostridium coccoides-Eubacterium rectale, or bifidobacterial probes in any of the tissue sections. Lactobacillus/Enterococcus signals were seen only occasionally in tissue sections of VSL#3 treated patients.

**DGGE analysis of the fungal microbiota**

Because fungi are a potent, yet little explored, element of the intestinal microbiota, DGGE analysis was used to investigate fungal diversity. Due to the specific characteristics of the 18S rRNA gene, separation of 18S rDNA fragments by genetic fingerprinting requires longer amplicons. Therefore, DGGE was used because the length of the amplicons for SSCP analysis is restricted to 400–500 bp. Fungal diversity, indicated as number of bands and as weighted diversity index, was reciprocal compared with bacterial diversity. In remission before therapy (that is, following induction by antibiotics), fungal diversity was high (n = 15). During both placebo (n = 5) and VSL#3 (n = 10) treatment, fungal diversity decreased. In the VSL#3 group, a marked reduction in fungal diversity was seen both in comparison with pretreatment levels (p = 0.001) and with the placebo group (p = 0.002) (Fig 8). Individual DGGE profiles showed wide interindividual variation in banding patterns. No consistent bands were identified using band matching analysis (Fig 9).

Separate statistical analysis of clinical, endoscopic, and histological PDAI scores revealed no significant correlation with fungal diversity.

**DISCUSSION**

The aetiology and pathogenesis of pouchitis is still unclear although ulcerative colitis and pouchitis share many similarities. This study investigated the influence of the probiotic agent VSL#3 on the bacterial microbiota in a placebo controlled clinical trial which was designed to assess the value of VSL#3 in maintaining antibiotic induced remission in patients with pouchitis. In pouchitis, bacterial overgrowth and a decrease in beneficial bacteria, in particular lactobacilli and bifidobacteria, in comparison with conventional ileostomy flora, has been described. It appears likely that faecal stasis and immune stimulation by stool bacteria play an important role in the development of pouch inflammation. The mucosa associated flora is probably of immediate relevance to the disease process and differs significantly from the composition of the ileal and midstream/faecal flora.

Morphological data from FISH analysis indicate that normal Enterobacteriaceae species (mainly *E. coli*) are found in uninfamed epithelium in ileoanal pouch biopsies (that is, from pouchitis patients who are in remission) in contrast with the normal ileum and colon of healthy volunteers in which no *E. coli* was found within the epithelium. When recurrent pouch inflammation occurred during placebo treatment, low bacterial diversity and a marked reduction in intramusosal Enterobacteriaceae species were found. The increase in Enterobacteriaceae within the mucosa during VSL#3 therapy indicates that remission maintenance under probiotics is associated with restoration of parts of the normal pouch flora.

For other relevant groups of intestinal bacteria, such as Bacteroides/Prevotella or the Lactobacilli/Bifidobacteria group, only sporadic signals were detected by FISH. The limited amount of mucosal biopsy material as well as the confined sensitivity of FISH analysis for single bacteria prompted us to complement the FISH results with PCR based molecular techniques.

The FISH results were supported by diversity analysis with SSCP and, at least in part, by taxa specific clone libraries. Successful maintenance of remission after VSL#3 treatment appeared to result in higher diversity of bacterial species that included members of the normal anaerobic enteric flora and not merely colonisation with strains contained only in VSL#3. With the exception of the Bacteroides/Prevotella group, the richness of bacteria was increased in the VSL#3 group compared with pretreatment levels. As diversity was increased during VSL#3 maintained remission, we suggest that this effect may be a component of the therapeutic mechanism of probiotics. The suggestion that low bacterial diversity could be an important mechanism for mucosal inflammation is supported by earlier investigations in which...
mucosal inflammation in IBD was associated with loss of normal anaerobic bacteria such as Bacteroides species, Eubacterium species, and Lactobacillus species. Restoration of Enterobacteriaceae species in the mucosa and the increase in bacterial diversity are observed in the setting of the clinical trial, which demonstrated successful remission maintenance by VSL\#3. The effects were observed on the specific background of remission induction with antibiotics. Antibiotics lead to significant alteration of the enteric bacterial balance. In neonates, antibiotic treatment induces complete eradication of Lactobacillus species together with a marked reduction in colonic total aerobic and anaerobic bacteria, in particular Enterobacteriaceae and Enterococci. The net effect of antimicrobial therapy therefore results in (i) a decrease in the total number of bacterial cells and (ii) a reduction in specific bacterial populations. Colonisation of the mucosa by Enterobacteriaceae species and diversification of Lactobacillus species and Bifidobacterium species in the VSL\#3 group might be facilitated by eradication of complex populations by the preceding antibiotic therapy and the diminished competition by other dominant bacterial consortia, such as Enterobacteriaceae or Enterococci. Therefore, expansion and diversification of the bacterial microbiota observed in the VSL\#3 group could be specific to pretreatment with antibiotics on the background of the dysbiotic flora in IBD. In fact, this may also be the case for the clinical efficacy of the treatment in pouchitis.

It is well documented that pouchitis is associated with loss of beneficial intestinal bacteria, especially the subgroups lactobacilli and bifidobacteria. We observed, as a net effect of VSL\#3 associated remission, reorganisation and diversification of the potentially beneficial Lactobacillus and Bifidobacterium flora. As most patients in the placebo group relapsed and almost all patients in the VSL\#3 group remained in remission, the specific effects of VSL\#3 and the effect of an inflammation free mucosa interact and therefore cannot be separated in this study. Additional therapeutic mechanisms induced by VSL\#3 treatment are possible that may be either primary or secondary to alteration of the constitution of the pouch microbiota. Specific induction of anti-inflammatory cytokines by probiotics could decrease the inflammatory activity in the mucosa and thereby provide better growth conditions for diversification of the flora. Rachmilewitz et al demonstrated in Toll-like receptor and MyD88 deficient mice that the immune stimulatory effect of probiotic bacteria isolated from the VSL\#3 compound was dependent on Toll-like receptor 9 signalling. Therefore, direct interaction of probiotic bacteria with mucosal immunoregulation could either induce anti-inflammatory pathways or directly interact with innate immune mechanisms as the primary mechanisms altering the growth conditions of the mucosal microbiota, or could be secondary to changes in microbial constitution and diversity. The significant difference between the placebo and the VLS\#3 groups indicates that VSL\#3 induced remission is associated with reconstruction of the intestinal flora, but investigation of the hierarchy of mechanistic events has to await further exploration in model systems. Fungi are important elements of the human flora. However, little is known about the composition of commensal fungal intestinal species. Fungal microbiotic diversity was inversely related to bacterial diversity. However, it has to be pointed out that fungal species represent only a small fraction of the total microbiota. Immunocompetent hosts have an efficient phagocytic capacity to prevent fungal invasion. It can be hypothesised that alteration in the balance of bacterial and fungal species in the mucosal flora reflects a metabolic dysbalance of the complex microbial ecosystem with pathophysiological consequences for the mucosal barrier. Most importantly, restored balance between bacterial and fungal diversity was seen in VSL\#3 treated patients. The question of whether the increase in fungal diversity is a direct result of higher bacterial diversity or an independent parallel effect remains unclear. Although fungi are normal members of the intestinal microbiota to a certain extent, fungal overgrowth is a typical complication of any bacterial imbalance following antibiotic therapy or a specific dietary regimen, as for example in intensive care units. Most likely the fungal overgrowth seen here was a direct consequence of bacterial dysbalance supported by diminished control mechanisms and reduced competition through the total bacterial microbiota. Studies on the mutual dependencies of the different parts of the intestinal microbiota are urgently needed to clarify this point.

Our study demonstrated that VSL\#3 maintained remission was accompanied by a higher bacterial and a reduced fungal diversity in comparison with placebo treatment. The increase in bacterial diversity was not caused by colonisation with bacterial strains contained in VSL\#3 but represents an independent effect. It is not unclear at present whether the anti-inflammatory and immunoregulatory effects of probiotics are primary or secondary to induction of changes in the diversity of the mucosal microbiota. Increase in bacterial diversity may be a therapeutic mechanism for the probiotic mixture VSL\#3 in maintenance of antibiotic induced remission in pouchitis. Methods for manipulating the complex microecology of the mucosal flora may be an important field for future therapeutic developments, especially addressing the secondary or primary prevention of pouchitis.

**ELECTRONIC DATABASE AND WEBSITE INFORMATION**

URLs used in this article are as follows:

- ARB software, ribosomal sequence database, and handling: http://www.arb-home.de
- Ribosomal Database Project II: http://rdp.cme.msu.edu/

**ACKNOWLEDGEMENTS**

This paper describes a substudy to a randomised, controlled, clinical trial of VSL\#3 versus placebo as maintenance therapy for pouchitis in remission, which has been reported separately. The work was supported by grants from the Deutsche Crohn und Kolitis Vereinigung (DCCV), the Crohn’s and Colitis Foundation of America (CCFA), the Deutsche Forschungsgemeinschaft (SFB 415), by Training and Mobility of Researchers (TMR-II) grant of the European commission, by the German Competence network IBD, and by the National Genome Research Network (both supported by the German Ministry of Education and Science (BMBF)). The authors thank the clinical investigators and the patients who provided research material for this study. The authors also thank Kornelia Smalla (Biologische Bundesanstalt für Land- und Forstwirtschaft, Institut für Pflanzenvirologie, Mikrobiologie und biologische Sicherheit, Braunschweig, Germany) for technical assistance with the DGGE analysis.

**Authors’ affiliations**

- T Kühbacher*, S J Ott*, S Schreiber, Department of General Internal Medicine, UKSH Campus Kiel, Kiel, Germany, and Institute for Clinical Molecular Biology, Christian-Albrechts-University Kiel, Germany
- U Helwig, U R Fölsch, Department of General Internal Medicine, UKSH Campus Kiel, Kiel, Germany
- T Mimura, M A Kamm, St Marks Hospital, London, UK
- F Rizzello, P Gionchetti, M Campieri, Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
EDITOR’S QUIZ: GI SNAPSHOT

Answer
From question on page 832

Absence of characteristic signs of Crohn’s colitis, such as segmental involvement, deep ulcerations, and fistula, and lack of a therapeutic response, made the formerly suspected diagnosis appear unlikely. Therefore, parasitological and bacteriological investigations were performed.

Microscopy of a fresh stool sample revealed erythrocystohagatic “magna-form” trophozoites of Entamoeba histolytica. Differentiation from apathogenic but morphologically identical Entamoeba dispar or Entamoeba moshkovskii was confirmed by positive anti-E. histolytica serum antibodies and a polymerase chain reaction specific for E. histolytica DNA from a faecal sample. Antiparasitic treatment with metronidazole and subsequently with diloxanide furoate and paromomycin resulted in almost complete regression of the disease.

In the past, parasitological investigations had not been considered because there was no history of travel to countries where amoebiasis is endemic. Thus amoebic colitis was misinterpreted as Crohn’s disease. Careful analysis of previous investigations revealed that the patient never had arthritis but polyarthrosis, probably due to his strenuous physical working activities. The source of amoeba infection was likely to be contaminated waste from the patient’s arthritic joint. The history of travel to countries where amoebiasis is endemic is a prerequisite for the diagnosis of amoebiasis.


doi: 10.1136/gut.2005.077487

REFERENCES
Author/s:
Blaut, M.; Campieri, M.; Folsch, U. R.; KAMM, M. A.; Schrieber, S.

Title:
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

Date:
2006

Citation:
Kuhbacher, T. Ott, S. J. Helwig, U. Mimura, T. Rizzello, F. Kleesen, B. Gionchetti, P. Blaut,
microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut, 55(6), 833-841.

Persistent Link:
http://hdl.handle.net/11343/25079

File Description:
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis